grant
A Randomized, placebo-controlled trial of the effects of Long-Acting GLP-1 or Dual Incretin (GLP-1 and GIP) Modulation on Gastrointestinal Functions and Relationship to Weight Loss
Organization MAYO CLINIC ROCHESTERLocation ROCHESTER, UNITED STATESPosted 1 Jul 2025Deadline 30 Apr 2028
NIHUS FederalResearch GrantFY2025APAPAcetamidophenolAcetaminophenAcetominophenAdult-Onset Diabetes MellitusAdverse ExperienceAdverse eventAgonistAnti-Obesity AgentsAnti-Obesity DrugsAntidiabetic HormoneAppetiteBody Weight decreasedBowel ObstructionClinical TrialsCountryD-GlucoseDataDesire for foodDevelopmentDextroseDoseDrugsEatingEligibilityEligibility DeterminationEndocrine Gland SecretionEndoscopyEsophagitisFDA approvedFatsFatty acid glycerol estersFoodFood IntakeFunding OpportunitiesFutureGLP-1GLP-1 receptorGLP-I receptorGastric EmptyingGastric StasisGastrointestinal MotilityGastroparesisGlp-1GlucagonGlucoseGlukagonHG-FactorHeterogeneityHormonesHydroxyacetanilideHyperglycemic-Glycogenolytic FactorIleusIndividualIngestionIntakeIntestinal ObstructionKetosis-Resistant Diabetes MellitusLiquid substanceLiteratureLungLung Respiratory SystemLung infectionsMaintenanceMaturity-Onset Diabetes MellitusMeasuresMedicationMotorNIDDMNauseaNon-Insulin Dependent DiabetesNon-Insulin-Dependent Diabetes MellitusNoninsulin Dependent DiabetesNoninsulin Dependent Diabetes MellitusNutrientObesityOver weightOverweightPalsyPancreatitisParacetamolParalysedParentsParticipantPatientsPharmaceutical PreparationsPlacebo EffectPlacebosPlegiaPrediabetesPrediabetes syndromePrediabetic StatePrevalenceProtocol ScreeningRandomized, Controlled TrialsReceptor ProteinRiskSatiationSham TreatmentSlow-Onset Diabetes MellitusSolidStable Diabetes MellitusStomachT2 DMT2DT2DMTachyphylaxisTherapeutic HormoneTimeType 2 Diabetes MellitusType 2 diabetesType II Diabetes MellitusType II diabetesUnited StatesVariantVariationWeightWeight LossWeight ReductionWithholding Treatmentadiposityadult adiposityadult obesityadult onset diabetesadults with obesityanti-obesity compoundsanti-obesity medicationsanti-obesity therapeuticsaspiratebody weight losscessation of treatmentclinical relevanceclinically relevantcorpulencedelayed gastric emptyingdevelopmentaldrug/agentendoscopic imagingexpectancy effectexpectation effectfluidgastricgastrointestinalgastrointestinal functionglucagon-like peptide 1glucagon-like peptide-1 receptorhazardindividual heterogeneityindividual variabilityindividual variationingestinsulin secretionintestine obstructionketosis resistant diabetesliquidliraglutidematurity onset diabetesnoceboobese patientsobesity interventionobesity therapyobesity treatmentover-weight adultsoverweight adultsparalysisparalyticparentpatients with obesitypharmacologicpilot trialplacebo control trialplacebo controlled trialplacebo responsepre-diabetespre-diabeticprediabeticpulmonarypulmonary infectionsrandomized control trialrandomized placebo control trialrandomized placebo controlled trialreceptorresponsesatietysham therapystomach emptyingtreatment cessationtype 2 DMtype II DMtype two diabetesweightswt-loss
Description preview
ABSTRACT
Obesity prevalence continues to increase in our country and worldwide. The incretins, GIP and GLP-1,
facilitate disposal of ingested nutrients and lead to glucose-dependent insulin secretion or inhibition of
glucagon secretion. Medications targeting these receptors are effective in inducing weight loss;
however, they are frequently…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click